Citagem Drug Interactions

No confirmed interactions have been reported with the use of gemcitabine. No specific drug interaction studies have been conducted.
Radiation Therapy: A pattern of tissue injury usually associated with radiation toxicity has been reported in association with concurrent and non-concurrent use of gemcitabine and radiation therapy. Radiosensitizing activity of gemcitabine was observed in preclinical and clinical studies when the drug was administered with or within 7 days of radiation therapy (i.e., concurrent therapy). Gemcitabine has been associated with radiation recall reactions, but administration more than 7 days before or after radiation therapy (i.e., non-concurrent therapy) does not otherwise appear to enhance toxicity. Available data suggest that gemcitabine therapy may be initiated once the acute effects of radiation therapy have resolved, or at least one week following radiation therapy.
Vaccine Use: Yellow fever and other live attenuated vaccines are not recommended in patients treated with gemcitabine due to the risk of systemic, possibly fatal disease, particularly in immunosuppressed patients.